CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men

AIDS

Volumn 20, Issue 14, 2006, Pages 1879-1883

  Thomas, Susan M ^a   Tse, Doris B ^a   Ketner, D Scott ^a   Rochford, Gemma ^a   Meyer, Daniel A ^a   Zade, David D ^b   Halkitis, Perry N ^b   Nádas, Arthur ^a   Borkowsky, William ^a   Marmor, Michael ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

CCR5 expression; CCR5 32; CCR5 59029; CD4+ monocytes; CD4+ T cells; HIV 1 seronegative

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE DURATION; FLOW CYTOMETRY; GENE MUTATION; GENETIC POLYMORPHISM; GROUPS BY AGE; HOMOSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE LINEAR REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SELF REPORT; SEXUAL BEHAVIOR; T LYMPHOCYTE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; GENOTYPE; HIV SERONEGATIVITY; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CCR5; RISK-TAKING; SEXUAL BEHAVIOR; TIME FACTORS;

EID: 33748512788     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000244207.49123.ff     Document Type: Article

References (22)

1. Paxton WA, Liu R, Kang S, Wu LJ, Gingeras TR, Landau NR, et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998; 244:66-73.
2. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999; 163:4597-4603.
3. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
4. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997; 185:1681-1691.
5. Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001; 27:472-481.
6. Salkowitz JR, Bruse SE, Meyerson H, Valdez H, Mosier DE, Harding CV, et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol 2003; 108:234-240.
7. Kostrikis LG. Impact of natural chemokine receptor polymorphisms on perinatal transmission of human immunodeficiency virus type 1. Teratology 2000; 61:387-390.
8. de Souza PR, Arraes LC, de Lima Filho JL, Bruneska D, Milanese M, Crovella S. CCR5 promoter polymorphisms and HIV-1 perinatal transmission in Brazilian children. J Reprod Immunol 2006; 69:77-84.
9. Mangano A, Kopka J, Batalla M, Bologna R, Sen L. Protective effect of CCR2-64I and not of CCR5-delta32 and SDF1-3′A in pediatric HIV-1 infection. J Acquir Immune Defic Syndr 2000; 23:52-57.
10. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 2004; 18:729-738.
11. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440.
12. Halkitis PN, Zade DD, Shrem M, Marmor M. Beliefs about HIV non-infection and risky sexual behavior among MSM. AIDS Educ Prev 2004; 16:448-458.
13. Kostrikis LG, Tyagi S, Mhlanga MM, Ho DD, Kramer FR. Spectral genotyping of human alleles. Science 1998; 279:1228-1229.
14. John GC, Bird T, Overbaugh J, Nduati R, Mbori-Ngacha D, Rostron T, et al. CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality. J Infect Dis 2001; 184:89-92.
15. Easterbrook PJ, Rostron T, Ives N, Troop M, Gazzard BG, Rowland-Jones SL. Chemokine receptor polymorphisms and human immunodeficiency virus disease progression. J Infect Dis 1999; 180:1096-1105.
16. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Piao L, Sakai K, et al. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes 2002; 51:238-242.
17. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, Stewart GJ. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. AIDS 2000; 14:103-108.
18. Passam AM, Zafiropoulos A, Miyakis S, Zagoreos I, Stavrianeas NG, Krambovitis E, Spandidos DA. CCR2-64I and CXCL12 3′A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy. J Clin Virol 2005; 34:302-309.
19. Hladik F, Liu H, Speelmon E, Livingston-Rosanoff D, Wilson S, Sakchalathorn P, et al. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism - 2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005; 79:11677-11684.
20. Connor RI, Paxton WA, Sheridan KE, Koup RA. Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1. J Virol 1996; 70:8758-8764.
21. Smith PD, Li L, Meng G. Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179 (suppl 3):S436-S440.
22. Smith PD, Meng G, Salazar-Gonzalez JF, Shaw GM. Macrophage HIV-1 infection and the gastrointestinal tract reservoir. J Leukoc Biol 2003; 74:642-649.